Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure

AIMS: Large‐scale clinical trials have demonstrated clinical benefits of sacubitril–valsartan in symptomatic heart failure with reduced ejection fraction patients (PARADIGM‐HF), with potential benefits in patients hospitalized for acute decompensated heart failure (ADHF) (PIONEER‐HF) and fewer benef...

Descripción completa

Detalles Bibliográficos
Autores principales: Carballo, David, Stirnemann, Jérôme, Garin, Nicolas, Marti, Chistophe, Serratrice, Jacques, Carballo, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261587/
https://www.ncbi.nlm.nih.gov/pubmed/32167679
http://dx.doi.org/10.1002/ehf2.12676

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261587/
https://www.ncbi.nlm.nih.gov/pubmed/32167679
http://dx.doi.org/10.1002/ehf2.12676

Ejemplares similares